R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B-cell Lymphoma Recurrent Clinical Trial

— FIL_POLARDHAP  

Official title:

Phase II Randomized Clinical Trial to Evaluate the Efficacy of the Addition of Polatuzumab Vedotin to Standard Chemotherapy R-DHAP (POLA-R-DHAP) as Induction Pre-transplantation Therapy in Patients With Diffuse Large B-Cell Lymphoma Refractory/Relapsed After First Line Treatment.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05966233
• Other study ID #: FIL_POLA-R-DHAP
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: January 2024
• Est. completion date: January 2029

Study information

• Verified date: December 2023
• Source: Fondazione Italiana Linfomi - ETS
• Contact: Uffici Studi FIL
• Phone: +390131033153
• Email: startup[@]filinf.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, multicenter, open label, phase II randomized clinical trial in DLBCL patients relapsed or refractory to first line R-chemo, aged 18-70 years and candidate to autologous transplant. Patients will be randomized 1:1 to received 4 cycles of R-DHAP or R-DHAP plus Polatuzumab Vedotin as induction treatment plus autologous transplant.

Description:

Prospective, multicenter, open label, phase II randomized clinical trial in DLBCL patients relapsed or refractory to first line R-chemo, aged 18-70 years and candidate to autologous transplant. Patients will be randomized 1:1 to received 4 cycles of R-DHAP or R-DHAP plus Polatuzumab Vedotin as induction treatment. PET-CT scan performed after induction be centrally review for disease response. Responding patients (CR) after induction will be addressed to receive Autologous Stem Cells Transplantation (ASCT) consolidation as per local guidelines. Patients achieving PR can proceed with ASCT or with a 3rd-line treatment, according to the physician judgment. Patients in SD/PD will be diverted to salvage strategies.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 150
• Est. completion date: January 2029
• Est. primary completion date: January 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Histologically documented diagnosis of Diffuse Large B-Cell Lymphoma Not otherwise specified (DLBCL-NOS) as defined in the 2022 edition of the World Health Organization

(WHO) classification; are also admitted documented diagnosis of:

• T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)
• Epstein-barr virus (EBV)-associated DLBCL
• Double-hit and triple-hit high grade B-cell lymphomas (HGBL DH/TH)
• High-grade B-cell lymphoma, NOS (HGBL)
• Transformed FL not previously untreated
• Follicular large B-cell lymphoma (FLBL, former follicular 3b)

2. Known availability of biopsy material (at relapse/refractory or previous most recent). Re-biopsy highly encouraged even if not mandatory. Central pathology review required, but not mandatory for registration and treatment start;

3. Relapse or refractoriness after the first line R-chemo (R-CHOP o similar). Previous treatment with polatuzumab containing regimen is allowed as per clinician judgment;

4. CAR-T not indicated or unavailable;

5. Age 18-70 years. sGA mandatory for patients 65-70 years old: only category FIT admitted [20] (see Appendix A);

6. Eastern Cooperative Oncology Group (ECOG) performance status = 2 if not related to lymphoma disease (see Appendix B);

7. Measurable disease = 1.5 cm in longest diameter, and measurable in 2 perpendicular dimensions;

8. Normal blood count defined as: neutrophils at least 1.500/mmc, platelets at least 75.000/mmc, haemoglobin at least 8,0 g/dL with transfusion independence, unless abnormalities due to underlying disease (bone marrow involvement), at the moment of signing informed consent;

9. Adequate liver function, assessed by baseline laboratory values; the increase to up to 2.5 ULN for transaminases and up to 1.5 ULN for bilirubin admitted for cases with documented liver involvement by lymphoma;

10. Adequate renal function defined as creatinine clearance = 40 mL/min (Cockcroft-Gault formula; see Appendix C)

11. Subjects HBsAg negative but positive for antibodies to hepatitis B core antigen with undetectable HBV-DNA measured by real-time polymerase chain reaction (PCR).

12. Women of childbearing potential (WOCBP) and men must agree to use effective contraception if sexually active. Females of childbearing potential and males with female partners of reproductive potential should be advised to use effective contraception while receiving polatuzumab vedotin and for 9 months after the last dose of polatuzumab vedotin for female patients and for 6 months after the last dose of polatuzumab vedotin for male patients with female partners of reproductive potential. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control method (failure rate of less than 1%) e.g. intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner. The use of condoms by male patients is required (even if surgically sterilized, i.e., status post vasectomy) unless the female partner is permanently sterile. Full sexual abstinence is admitted when this is in line with the preferred and usual lifestyle of the subject, for the same time period planned for other methods of birth control (see above). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods for the female partner) and withdrawal are not acceptable methods of contraception

13. WOCBP must have a negative serum (beta-human chorionic gonadotropin [b-hCG]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study;

14. Life expectancy > 6 months;

15. Subject understands and voluntarily signs an informed consent form approved by the National Ethics Committee prior to the initiation of any screening or study-specific procedures;

16. Subject must be able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

1. Any histology other than DLBCL

2. Primary mediastinal lymphoma (PMBCL)

3. Known central nervous system lymphoma

4. Known history of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies

5. Contraindication to any drug in the chemotherapy regimen

6. Left ventricular ejection fraction (LVEF) < 50%

7. Neuropathy = grade 2

8. Subject is:

• Seropositive for hepatitis B, defined by a positive test for hepatitis B surface antigen [HBsAg]. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (HBsAb positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR
• Known to be seropositive for hepatitis C. EXCEPTION: Patients with presence of HCV antibody, but PCR negative for HCV-RNA are eligible
• Positive for human immunodeficiency virus (HIV) infection

9. Any uncontrolled active systemic infection requiring intravenous (IV) antibiotics

10. History of stroke or intracranial hemorrhage within the past 6 months.

11. History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances

12. Clinically significant cardiovascular disease

13. Major surgical intervention prior 4 weeks to enrollment if not due to lymphoma and/or other disease life-threatening that can compromise chemotherapy treatment

14. Prior malignancies other than lymphoma in the last 5 years with exception of currently treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix

15. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety

16. If female, the patient is pregnant or breast-feeding

17. Patients participating in other clinical studies

Related Conditions & MeSH terms

• Diffuse Large B Cell Lymphoma Refractory
• Diffuse Large B-cell Lymphoma Recurrent
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse

Intervention

Drug:
• R-DHAP
Rituximab 375 mg/m2 IV on D0 or D1 Dexamethasone 40 mg/day IV or PO on D1-4 Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3 Cisplatin 100 mg/ m2 IV on D1
• Pola-R-DHAP
Polatuzumab Vedotin 1.8 mg/kg IV on D1 Rituximab 375 mg/m2 IV on D0 or D1 Dexamethasone 40 mg/day IV or PO on D1-4 Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3 Cisplatin 100 mg/ m2 IV on D1

Locations

Country	Name	City	State
Italy	A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia	Alessandria
Italy	AOU Ospedali Riuniti, Clinica di Ematologia	Ancona
Italy	Azienda Ospedaliera S.Giuseppe Moscati, S.C. Ematologia e Trapianto emopoietico	Avellino
Italy	IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuto-correlati	Aviano
Italy	IRCCS Istituto Tumori Giovanni Paolo II, U.O.C Ematologia	Bari
Italy	Cliniche Humanitas Gavazzeni, Oncologia	Bergamo
Italy	ASST Spedali Civili di Brescia, Ematologia	Brescia
Italy	Fondazione del Piemonte per l'Oncologia - IRCCS, Ematologia	Candiolo
Italy	Arnas Nuovo Ospedale Garibaldi Nesima, U.O.C. Ematologia	Catania
Italy	A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo	Cuneo
Italy	Azienda Ospedaliera Universitaria Careggi, Unit? funzionale di Ematologia	Firenze
Italy	Ospedale Vito Fazzi, Ematologia	Lecce
Italy	ASST Ovest Milanese - Legnano, U.O.C. Ematologia	Legnano
Italy	ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia	Milano
Italy	Istituto Scientifico San Raffaele, Unit? Linfomi - Dipartimento Oncoematologia	Milano
Italy	Ospedale Maggiore Policlinico - Fondazione IRCCS Ca Granda, Ematologia	Milano
Italy	Fondazione IRCCS San Gerardo dei Tintori, Ematologia	Monza
Italy	AOU Maggiore della Carit? di Novara, SCDU Ematologia	Novara
Italy	A.O. Ospedali Riuniti Villa Sofia-Cervello, Divisione di Ematologia	Palermo
Italy	Ospedale S. Maria della Misericordia, Ematologia	Perugia
Italy	P.O. Spirito Santo di Pescara, UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi	Pescara
Italy	Ospedale Guglielmo da Saliceto, U.O.Ematologia	Piacenza
Italy	AOU Pisana, U.O. Ematologia	Pisa
Italy	A.O.R. "San Carlo", U.O. Ematologia	Potenza
Italy	Ospedale delle Croci, Ematologia	Ravenna
Italy	Azienda Unit? Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia	Reggio Emilia
Italy	AO San Giovanni Addolorata, S.C. Ematologia	Roma
Italy	AO Sant Andrea, Ematologia	Roma
Italy	Policlinico Umberto I - Universit? "La Sapienza", Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione	Roma
Italy	Policlinico Universitario Campus Bio-Medico, Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulare	Roma
Italy	Istituto Clinico Humanitas, U.O. Ematologia	Rozzano
Italy	AOU Senese, U.O.C. Ematologia	Siena
Italy	A.O.U. Citta della Salute e della Scienza di Torino, Ematologia Universitaria	Torino
Italy	A.O.U. Citta della Salute e della Scienza di Torino, S.C.Ematologia	Torino
Italy	Ospedale Ca Foncello, S.C di Ematologia	Treviso
Italy	A.O.C. Panico, U.O.C Ematologia e Trapianto	Tricase
Italy	Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), SC Ematologia	Trieste

Sponsors (2)

Lead Sponsor	Collaborator
Fondazione Italiana Linfomi - ETS	Roche Pharma AG

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival (PFS)	Time between the randomization to first documentation of recurrence, progression or death from any cause	From treatment start up to 30 months (6 months treatment period and 24 months of follow-up)
Secondary	Event-Free Survival (EFS)	Time between the randomization to any treatment failure, including disease progression, or discontinuation of treatment for any reason (e.g., disease progression, toxicity, patient preference, initiation of a new treatment without documented progression) or death from any cause.	From treatment start up to 30 months (6 months treatment period and 24 months of follow-up)
Secondary	Complete response rate (CRR)	CRR will be defined according to Response Criteria for NHL with PET (Lugano 2014). CRR will include only patients who achieved a CR and will be evaluated on assessed patients and on all treated patients, considering patients without a response assessment (due to any reason) as non-responders.	From treatment start up to end of treatment evaluation (about 6 months)
Secondary	Overall response rate (ORR)	ORR will be defined as the proportion of patients who have a partial or complete response to therapy (CR+PR).	From treatment start up to end of treatment evaluation (about 6 months)
Secondary	Overall Survival (OS)	Time between randomization to death from any cause.	From treatment start up to 30 months (6 months treatment period and 24 months of follow-up)
Secondary	Incidence and severity of AEs	Incidence and severity of AEs in R-DHAP vs POLA-R-DHAP according to latest CTCAE criteria during induction immunochemotherapy	From start to end of induction treatment evaluation (about 3 months)
Secondary	Adequate stem cells mobilization	Adequate stem cells mobilization will be defined by the target cell harvesting of 3 x 10^6 CD34+ cells/kg	From beginning of 2nd cycle to end of induction treatment evaluation (about 2 months)
Secondary	Autologous consolidation feasibility	Proportion of patients receiving autologous consolidation after POLA-R-DHAP vs R-DHAP	At time of end of treatment assessment (up to 6 months from treatment begin)